Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

NOVARTIS AG (NOVN)

276
Delayed Quote. Delayed BATS Europe - 07/07 11:29:59 am
92.525 CHF   -0.46%
05:46pDJNovartis Heart Failure Drug Approved by FDA
05:43pDJNovartis Heart Failure Drug Approved by FDA
04:59p NOVARTIS : FDA approves new heart failure pill from Novartis
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Novartis Heart Failure Drug Approved by FDA

07/07/2015 | 05:46pm US/Eastern

Novartis AG's Entresto drug has been approved by the U.S. Food and Drug Administration for the treatment of heart failure.

The FDA's decision is based on a study that enrolled nearly 8,5000 patients. The study ended early when it showed that Entresto "significantly" reduced the risk of death when compared with a treatment called enalapril, according to the Swiss pharmaceutical company.

The treatment, also known as sacubitril/valsartan, is usually prescribed alongside other heart failure therapies for patients with reduced ejection fraction, meaning their heart muscle that doesn't contract effectively.

Entresto is undergoing review in several countries and, if approved, could have sales of more than $5 billion, Novartis said.

It added that nearly six million people in the U.S. have heart failure, of which about half have the form with reduced ejection fraction.

Novartis most recently reported a rise in first-quarter earnings, after it closed deals with GlaxoSmithKline and Eli Lilly and Co.

Write to Angela Chen at angela.chen@dowjones.com

Access Investor Kit for Novartis AG

Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=CH0012005267

Access Investor Kit for Eli Lilly & Co.

Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=US5324571083

Access Investor Kit for Novartis AG

Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=US66987V1098

React to this article
Latest news on NOVARTIS AG
05:46pDJNovartis Heart Failure Drug Approved by FDA
05:43pDJNovartis Heart Failure Drug Approved by FDA
04:59p NOVARTIS : FDA approves new heart failure pill from Novartis
04:35p NOVARTIS : ' new heart failure medicine LCZ696, now called Entresto(TM), approve..
07/06 NOVARTIS : Alcon Research Assigned Patent
07/06 NOVARTIS : Spinifex Pharmaceuticals to be Acquired by Novartis
07/06 NOVARTIS : Sudden spurt in Novartis
07/05 NOVARTIS : 'More efforts needed worldwide to prevent eye diseases'
07/04 CATALENT : Makes Two Key European Appointments in Oral Dose Manufacturing
07/02 Ergomed Appoints Andrew Mackie As Executive Director
Advertisement
Chart
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Income Statement Evolution
More Financials